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Abstract
Background: Depression is a common psychiatric disorder characterized by a high rate of relapse and recurrence.
The most commonly used strategy to prevent relapse/recurrence is maintenance treatment with antidepressant
medication (mADM). Recently, it has been shown that Mindfulness-Based Cognitive Therapy (MBCT) is at least as
effective as mADM in reducing the relapse/recurrence risk. However, it is not yet known whether combination
treatment of MBCT and mADM is more effective than either of these treatments alone. Given the fact that most
patients have a preference for either mADM or for MBCT, the aim of the present study is to answer the following
questions. First, what is the effectiveness of MBCT in addition to mADM? Second, how large is the risk of relapse/
recurrence in patients withdrawing from mADM after participating in MBCT, compared to those who continue to
use mADM after MBCT?
Methods/design: Two parallel-group, multi-center randomized controlled trials are conducted. Adult patients with
a history of depression (3 or more episodes), currently either in full or partial remission and currently treated with
mADM (6 months or longer) are recruited. In the first trial, we compare mADM on its own with mADM plus MBCT.
In the second trial, we compare MBCT on its own, including tapering of mADM, with mADM plus MBCT. Follow-up
assessments are administered at 3-month intervals for 15 months. Primary outcome is relapse/recurrence.
Secondary outcomes are time to, duration and severity of relapse/recurrence, quality of life, personality, several
process variables, and incremental cost-effectiveness ratio.
Discussion: Taking into account patient preferences, this study will provide information about a) the clinical and
cost-effectiveness of mADM only compared with mADM plus MBCT, in patients with a preference for mADM, and
b) the clinical and cost-effectiveness of withdrawing from mADM after MBCT, compared with mADM plus MBCT, in
patients with a preference for MBCT.
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Background
Major depressive disorder (MDD) is one of the most
prevalent psychiatric disorders characterized by high re-
lapse and/or recurrence rates. Relapse is defined as ‘a re-
turn of symptoms satisfying the full syndrome criteria
for an episode that occurs during the period of remis-
sion, but before recovery’, where remission is a period in
which the individual no longer meets syndrome criteria
for the disorder and has no more than minimal symp-
toms, and recovery is being in remission for 6 months
or longer; recurrence is ’ the appearance of a new epi-
sode of MDD occurring during recovery’ [1]. In a large
prospective study, a recurrence rate of 85% was observed
in outpatients with MDD during a follow-up period of
15 years [2]. Furthermore, the recurrence risk has been
shown to increase with 16% after each successive epi-
sode [3]. Given the high psychological as well as social
and economic burden associated with MDD, relapse/
recurrence prevention is extremely important. The most
commonly used strategy to prevent relapse/recurrence is
maintenance treatment with antidepressant medication
(mADM). International guidelines recommend that
patients with recurrent MDD should continue mADM
for at least two years after remission [4]. A meta-analysis
showed that mADM reduces relapse/recurrence rates
significantly compared to placebo (18% versus 41%)
based on 31 randomized controlled trials with follow-up
periods ranging from 6 to 36 months [5]. However, des-
pite the established effectiveness of mADM as a prevent-
ive strategy, it has several disadvantages. First, many
patients are unwilling to continue mADM for a longer
period [6] and adherence is typically low [7]. Second,
many patients experience disturbing side effects [8].
Moreover, many patients prefer psychological over
pharmacological treatment [9]. Psychotherapeutic
approaches also seem to have long-term beneficial
effects, whereas effects of mADM cease after discontinu-
ation [10]. To address the need for psychological inter-
ventions targeting relapse prevention, Segal, Williams
and Teasdale developed Mindfulness-Based Cognitive
Therapy (MBCT) [11]. The aim of MBCT is not to
change or eliminate depressive symptoms, but rather to
relate to them in a different way, i.e. with a more accept-
ing, mild attitude. The rationale behind the MBCT pro-
gram is based on an empirically supported, theoretical
framework suggesting that patients with recurrent de-
pression become more vulnerable to developing depres-
sion as cognitive reactivity increases (for a review see
[12]). Cognitive reactivity refers to negative modes of
thinking and behaving that are reactivated in periods of
stress or low mood. It is suggested that these (automatic)
negative reactions in turn, lead to a further lowering of
mood, eventually turning into a depressive relapse/recur-
rence [13]. Cognitive reactivity is strongly related to
rumination, which refers to recurrently thinking about
one’s depressive symptoms and their possible causes and
implications. Rumination is thought to be an important
cognitive vulnerability factor for both onset and relapse/
recurrence in depression [14,15]. MBCT is targeted at
recognizing these cognitive and behavioral reactions to
low mood or other stressful situations, and to observe
these reactions with acceptance and kindness and from a
wider, decentered perspective. Indeed, there is evidence
that MBCT diminishes the ‘toxic’ relationship between
post-treatment cognitive reactivity and depressive relapse
[16] and that decreased rumination mediates the effects
of MBCT [17]. Unlike cognitive reactivity and rumin-
ation, self-compassion seems to be a beneficial factor that
is protective against depression. Self-compassion can be
described as a combination of (a) self-kindness - being
kind and understanding toward oneself in instances of
pain or failure, (b) common humanity - perceiving one’s
experiences as part of the larger human experience, and
(c) mindfulness - holding painful thoughts and feelings in
balanced awareness [18]. Evidence suggests that both
self-compassion and mindfulness skills mediate the effect
of MBCT on relapse/recurrence [16]. Three randomized
controlled trials (RCTs) have shown that MBCT in
addition to treatment as usual (TAU) significantly
reduced the relapse/recurrence risk compared with TAU
alone, over a period of 14 months [19-21]. In the first
two trials [19,20], beneficial effects of MBCT were seen
in patients with three or more past episodes, whereas no
difference in relapse/recurrence percentages between
MBCT and TAU was observed in patients with two past
episodes (but see [22] for positive effects of MBCT in
patients with one or two past episodes). Another trial has
shown that MBCT’s prophylactic effect is at least equal
to mADM for patients with three or more past episodes
[23]. This latter finding may specifically apply to patients
whose remission is unstable [24]. There is also evidence
that MBCT might reduce subthreshold depressive symp-
toms, an important risk factor for relapse/recurrence, in
patients remitted from MDD [22] and patients with
current MDD [17]. A recent meta-analysis [25] showed
that the overall risk ratio for relapse/recurrence after
MBCT is 0.66 (a relative risk reduction of 34%) com-
pared with TAU or placebo indicating that MBCT is indeed
an effective prophylactic intervention for patients with
recurrent MDD in remission. However, the prophylactic
effectiveness of the combination of MBCT plus mADM
has not yet been compared with either mADM or MBCT
on their own. More specifically, MBCT has not been stud-
ied as an additional treatment in patients continuing
mADM, rather than TAU, to prevent relapse/recurrence.
Also, up to now we do not know if continuing mADM after
MBCT has additional benefits over withdrawing from
mADM after MBCT. As more and more MBCT courses
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are available, answering these specific questions becomes
increasingly important for patients and clinicians in order
to find the optimal strategy to prevent relapse/recurrence.
The current study is designed to answer these questions.
Aims
The purpose of the ‘MOMENT’ study is twofold using
two separate but connected RCTs to answer the follow-
ing questions: 1) “In patients who are in remission of de-
pression, who are being prescribed mADM and who are
reluctant to discontinue medical treatment, is MBCT
when given as an add-on therapy superior to the con-
tinuation of medical treatment alone?” (mADM versus
mADM+MBCT) and 2) “In patients who are in remis-
sion of depression who are being prescribed mADM and
who are willing to try MBCT and not unwilling to dis-
continue medical treatment, is MBCT with a tapering
off regimen of the medical treatment not inferior to
MBCT in combination with continued medical treat-
ment?” (MBCT versus mADM+MBCT). Our primary
outcome is relapse and/or recurrence. Thus, the results
of this study will inform patients with MDD and mental
health professionals about the relapse and recurrence
risks associated with the different treatment options
given a certain treatment preference, and will support
decision making processes regarding these options. In
addition to these primary aims, we intend to examine; 3)
the effect of mADM versus mADM+MBCT on the time
to, number, duration and severity of relapse/recurrence,
quality of life, and personality; 4) the effect of MBCT
versus mADM+MBCT on the time to number, duration
and severity of relapse/recurrence, quality of life, and
personality; 5) several process variables such as MBCT
adherence, rumination, cognitive reactivity, mindfulness
skills, and self-compassion as possible mechanisms under-
lying the clinical effectiveness of MBCT; 6) the cost-
effectiveness of mADM versus mADM+MBCT and 7)
the cost-effectiveness of MBCT versus mADM+MBCT.
Methods
Design
Originally the study was designed as a single trial, ran-
domizing patients who are in remission of depression
over [a] continuation of medical treatment, [b] switching
to MBCT, or [c] MBCT as an add-on to medical treat-
ment. This protocol was approved by our ethical review
board (CMO Arnhem-Nijmegen) and registered under
number 2008/242. However, inclusion of patients was
hampered by the fact that many patients turned out to
have a strong treatment preference: some patients were
eager to start with MBCT and other patients were reluc-
tant to discontinue medical treatment. Continuing the
trial as a trial with preference arms would have resulted
in a substantial proportion of patients who would not
have been randomly allocated to treatment, introducing
a potential serious bias. We therefore decided to conduct
two separate RCTs, one with patients who are reluctant to
discontinue medical treatment, and one with patients who
are particularly eager to try MBCT and at least not unwill-
ing to discontinue medical treatment. In the former,
patients are randomly allocated to either continuation of
medical treatment, or continuation of medical treatment
with MBCTas an add-on therapy (a parallel-group, rando-
mized controlled superiority trial). In the latter, patients
are allocated to either MBCT while continuing medical
treatment, or to MBCT in combination with a tapering-
off regimen of the medical treatment (a parallel-group,
randomized controlled non-inferiority trial). In this way,
we take optimal account of the patient preferences and
the study population will be as representative as possible
of patients seen in routine clinical practice. The change in
protocol has been approved by the Medical Ethics Com-
mittee Arnhem-Nijmegen (20-02-2011). Here, we report
the design of the two trials. See Figure 1 for a flow chart
of the recruitment and study procedure.
Sample size
Trial 1: mADM versus mADM+MBCT
For trial 1 we need to recruit 96 participants (n = 48 per
group) in order to demonstrate a difference of 25% in re-
lapse/recurrence rates between mADM and mADM+
MBCT, with a power of 80% (alpha 0.05, one-sided).
This calculation is based on earlier studies reporting re-
lapse/recurrence percentages of 60% in the mADM
group [23] and approximately 38% in the MBCT plus
TAU group [25]. Because our trial investigates MBCT
plus mADM rather than MBCT plus TAU, we expect an
even lower relapse/recurrence percentage (about 35%) in
the combination group. Our expected difference is
therefore 60% (mADM) minus 35% (mADM+MBCT)
resulting in 25%.
Trial 2: MBCT versus mADM+MBCT
The sample size of trial 2 is based on the principle of
non-inferiority. According to the Draft Guidance for In-
dustry Non-Inferiority Clinical Trials of the US Food
and Drug Administration [26] non-inferiority should be
demonstrated by comparing the new, experimental treat-
ment with an established efficacious treatment. In the
case of relapse prevention in depression, this established
treatment is mADM. However, since a head to head
comparison of MBCT with mADM is complicated due
to our design, we compare MBCT with the combination
therapy (mADM+MBCT). We reasoned that the differ-
ence in relapse/recurrence between MBCT and
mADM+MBCT should not be larger than the difference
between the established treatment (mADM) and
mADM+MBCT, which is expected to be approximately
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25%. Therefore, we chose a non-inferiority margin of
25%. Based on this assumption, the sample size needed
in this non-inferiority trial is 280 in total (n = 140 per
group) with a power of 80% (alpha 0.05, one-sided).
Participants
The study protocol has been approved by the Medical
Ethics Committee Arnhem-Nijmegen (nr. 2008/242) for
all participating sites. Local Ethics Committees approved
local feasibility. Patients are included in the study only
after written informed consent has been obtained. Par-
ticipation is completely voluntary and patients can with-
draw from the study and/or treatment at any time
without having to give a reason for withdrawal and with-
out consequences for their treatment options. Suspected
serious adverse events are recorded and reported to the
Medical Ethics Committee Arnhem-Nijmegen. Patients
are recruited from nine centers across the Netherlands:
Department of Psychiatry, Radboud University Nijmegen
Medical Center; Department of Psychiatry, Academic
Medical Center, Amsterdam; GGZ inGeest, partner VU
University Medical Center, Amsterdam; Pro Persona
Ede, Tiel and Arnhem; Parnassia Bavo Psychiatric Insti-
tute, The Hague; PsyQ Psycho Medical Programmes,
The Hague; Leiden University Medical Center Leiden
and GGZ Rivierduinen, Leiden and Lisse; GGZ Centraal,
Amersfoort; and GGZ Noord-Holland-Noord, Alkmaar.
Recruitment was done via referrals from mental health
professionals and by media advertisements.
Inclusion criteria
Inclusion criteria for the MOMENT study are: a) MDD
with a history of at least three depressive episodes
according to the Diagnostic and Statistical Manual of
Mental Disorders - 4th edition (DSM-IV [27]) using the
Structured Clinical Interview for DSM disorders I
Recruitment via mental health professionals’ referrals, general practitioners’ 
referrals, media attention, posters and advertisements.
Interested individuals screened by telephone to assess eligibility after verbal 
consent is obtained. 
Does patient (probably) meet in- and exclusion criteria?
Yes
No Exclude 
Study procedure explained in detail and information is sent by mail. 
After ≥ week, the patient is contacted again. 
Patient still interested in participation? No Exclude
Patient is invited for the research interview, in which the in- and 
exclusion criteria are assessed in detail. Informed consent is taken.
Eligible and informed consent obtained?
Randomization (stratification variables: research centre; full vs. partial remission 
(IDS-C ≤ 11 versus > 11); number of depressions in the past (3-4 versus ≥ 5); 
Baseline questionnaires taken (T0).
Preference for MBCT Preference for continuing mADM
MBCT mADM + 
MBCT
mADM + 
MBCT
mADM
Assessments during MBCT 
Follow-up assessments at T1 (3 months post-randomization), T2 
(6 months), T3 (9 months), T4 (12 months) and T5 (15 months).
Medication consultations
Yes
No Exclude
Yes
Figure 1 Flow chart of the recruitment and study procedure.
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(SCID-I [28]); b) treated with a stable dose of mADM
over the last 6 months or longer; c) currently either in
full or partial remission. Full remission is defined in
our study as not currently meeting the criteria for a
depressive episode assessed by the SCID and having a
score of ≤ 11 on the Inventory of Depressive Symptom-
atology – Clinician rating (IDS-C30 [29]). Partial remis-
sion is defined as not currently meeting the criteria for
a depressive episode and having an IDS-C score > 11.
The cut-off point of ≤ 11 > on the IDS-C corresponds to
a Hamilton Rating Scale for Depression score of 8
which is often used as a cut-off score for remission
[30]; d) native Dutch speaking.
Exclusion criteria
We exclude people in case of: a) bipolar disorder any
primary psychotic disorder (current and previous), clin-
ically relevant neurological or other somatic illness and/
or current alcohol or drug dependency, assessed with
the Mini International Neuropsychiatric Interview
(MINI [31]); b) high dosage of benzodiazepines (> 2 mg
Lorazepam equivalents daily); c) recent electroconvulsive
therapy (< 3 months ago); d) previous MBCT/MBSR
course and/or extensive meditation experience (e.g.
retreats); e) current psychotherapy with a frequency of
more than once per three weeks and f) visual hearing or
cognitive impairments that impair the completion of
self-report questionnaires and interviews.
Interventions
mADM
All study participants are on a stable dose of mADM for
at least 6 months prior to enrollment (inclusion criterion).
In the mADM group participants continue their use of
mADM during the study period of 15 months. After
randomization, participants are seen by a study psych-
iatrist for a review of their mADM. For optimization of
mADM, psychiatrists taking part in the study use a proto-
col based on national [32] and international [33] guide-
lines, made applicable for the MOMENT study by two
experts in pharmacological treatment of MDD (WN and
MB). Switching or augmenting medication is allowed be-
tween T0 and T1, and recommendations to manage side
effects are provided. Compliance with mADM is measured
prospectively during the whole study period using a daily
calendar. Participants in the mADM condition are invited
to take part in the MBCT training after the study period if
they are interested.
mADM + MBCT
In the combination group participants are seen by a
psychiatrist for a review of their mADM as described
above, and are asked to continue their mADM during
the study period. In addition, these patients are invited
to take part in the MBCT training, a manualized group
skills-training program [11]. MBCT is based on the
protocol of Mindfulness-Based Stress Reduction (MBSR)
which was developed by Jon Kabat-Zinn [34] combined
with elements of Cognitive Behavioral Therapy (CBT
[35]), turning it into a relapse prevention programme for
patients with recurrent depression. The training consists
of eight weekly sessions in a group (8 – 15 participants)
with a duration of 2.5 hours, plus one day of silent prac-
tice between the 6th and 7th session. The silent day, al-
though originally not in the MBCT program, was
incorporated following the MBSR protocol [34] to give
participants the opportunity to deepen their mindfulness
practice. Formal meditation exercises that are part of the
program are the body scan, sitting meditation, walking
meditation and mindful movement. The program also
encourages participants to cultivate awareness of every-
day activities, such as eating or taking a shower. Cogni-
tive techniques that are part of the program are
education, monitoring and scheduling of activities, iden-
tification of negative automatic thoughts and devising a
relapse prevention plan. Participants are expected to
practice meditation at home for about an hour a day. In
addition, participants in the MBCT conditions are
invited to take part in three booster sessions every three
months during the study period (around 3, 6 and
9 months after MBCT) to enhance their mindfulness
practice through peer and teacher support and rehearsal
of the key components of MBCT. Delivery of MBCT and
check for competence and adherence. MBCT courses are
provided at 12 different locations in the Netherlands and
are led by one or two MBCT teachers per site. MBCT
teachers were trained in the study protocol for MBCT
during a 3-day training retreat in the beginning of the
project, as well as at three subsequent training days
every 6 months. Teaching sessions of each (pair of )
teacher(s) are videotaped to check treatment integrity.
Two tapes per teacher are randomly selected and rated
by highly experienced MBCT/MBSR trainers. Compe-
tence and adherence are evaluated with the
Mindfulness-Based Interventions – Teaching Assess-
ment Criteria [36].
MBCT (with tapering of mADM)
In the ‘MBCT only’ condition participants are invited to
take part in the MBCT course as described above. In
addition, they are asked to taper off their mADM from
session 7 of the MBCT course onwards. The protocol
specifies a tapering scheme lasting 5 weeks for all com-
mon ADMs, especially addressing procedures to handle
symptoms characteristic for discontinuation [37] (avail-
able on request). In case of more exceptional treatments
(e.g. lithium addition) withdrawal is based on the shared
opinion of the authors of the medication protocol.
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Clients are seen by a consultant psychiatrist for a mini-
mum of 3 and a maximum of 12 appointments. The first
three consultations are scheduled around session 1
(informing and preparing participants), session 7 (initiat-
ing withdrawal) and approximately four weeks after ses-
sion 7 (evaluation of withdrawal). If more guidance is
needed, additional appointments can be scheduled.
Patients are reassured that they can restart ADM as
soon as they suffer a relapse/recurrence, or when with-
drawal proves to be unfeasible.
Outcome measures
Table 1 presents an overview of the outcome measures
and the time points of assessments.
Primary outcome measure
Relapse/recurrence. Relapse/recurrence is defined as
meeting the DSM-IV criteria for a depressive episode at
any moment during follow-up assessed by research
assistants using the SCID-I. Our follow-up period has a
duration of 15 months, therefore both relapse and recur-
rence can be observed. We refer to ‘relapse’ in case of a
depressive episode occurring within 6 months after full
remission and we refer to ‘recurrence’ in case of a de-
pressive episode occurring after 6 months of full remis-
sion. In general, we refer to ‘relapse/recurrence’ to
indicate a depressive episode within the study period. In
order to prevent attrition and recall bias, the interviews
(either face-to-face or by telephone) are performed at
3 months intervals (T1-T5). At any interview assistants
review the previous 3 months since the previous contact.
The research assistants received one full day of training
to use the SCID-I. Interviews are audio taped to allow
second-rating by an independent and blind assessor in
cases of actual, borderline or probable relapse/recur-
rence. Previous studies on inter-rater reliability of the
SCID-I have reported Cronbach’s alpha values between
0.61 and 0.80 [38,39].
Secondary outcome measures
Time to relapse/recurrence is calculated from baseline
to first relapse or recurrence. Number of relapses/
recurrences during the follow-up period is calculated.
Duration of relapse/recurrence is expressed in two
ways: first as the duration of the first relapse/recur-
rence and second, as the percentage depressed days
(including multiple depressive episodes) of the total
number of follow-up days. Severity of depressive symp-
toms at follow-up contacts is assessed using the Dutch
version of the IDS-C [29]. The IDS-C has good psy-
chometric qualities [40,41]. When the IDS-C is not
administered during a depressive episode which falls in
between assessments, the number of depressive symp-
toms according to the SCID-I (5 to 9) is used as a
measure of severity. Quality of life is assessed using the
26-item self-report WHOQOL short version (WHO-
QOL-bref [42]) which assesses subjective quality of life
in four domains: physical, psychological, social and en-
vironmental. Personality is measured with the NEO
Personality Inventory Revised (NEO-PI-R [43]) which
consists of five domains: neuroticism, extraversion, open-
ness, altruism, and conscientiousness.
Process data
Adherence to MBCT and adherence to mADM is
assessed during the entire study period using a calendar
Table 1 Overview of the measures and corresponding time points
Measure Target concept T0 MBCT T1 T2 T3 T4 T5
SCID-I* Diagnosis of (recurrent) MDD ● ● ● ● ● ●
IDS-C Current depressive symptoms ● ● ● ● ● ●
CSRI (Mental) health service use ● ● ● ● ● ●
MMAS Medication adherence ● ● ● ● ● ●
RRS Rumination ● ● ●
LEIDS Cognitive reactivity ● ● ●
FFMQ Mindfulness skills ● ● ●
SCS Self-compassion ● ● ●
WHOQOL-bref Quality of Life ● ● ●
EQ-5D Quality of Life ● ● ● ● ● ●
NEO-PI-R Personality ● ●
MAAS Daily awareness/attention ●
I-PANAS-SF Positive and negative affect ●
Calendar Mindfulness and medication adherence, absence from work and health service use Monthly during 15-month study period.
Note. * Module depression (current and/or in the past).
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on which patients register on a daily basis their adherence
to mindfulness exercises formal, informal, or none - and
their adherence to mADM - full adherence, partial adher-
ence (e.g. lower dosage than prescribed), or no adherence.
This information is combined with the 4-item Morisky
Medication Adherence Scale (MMAS [44]) with scores
ranging from 0 (perfect adherence) to 4 (low adherence).
Rumination is measured with the extended version of the
Ruminative Response Scale (RRS-EXT [45]). The RRS-
EXT enables distinction between ‘reflection’ and ‘brooding’,
the former referring to a more adaptive, and the latter to a
more maladaptive way of thinking about depression.
Cognitive reactivity is assessed using the Leiden Index of
Depression Sensitivity – Revised (LEIDS-R [46]). This scale
consists of six subscales: hopelessness/suicidality, accept-
ance/coping, aggression, control/perfectionism, risk aver-
sion, and rumination. To examine mindfulness skills, we
administer the Dutch Five Facet Mindfulness Questionnaire
(FFMQ [47]). The scale consists of 39 items divided into
the subscales observing, describing, acting with awareness,
nonjudging and nonreactivity. Self- compassion is measured
with the Self Compassion Scale (SCS [48]). The SCS has 26
items measuring three concepts that are related to self-
compassion: a) self-kindness versus self-judgment, b) com-
mon humanity versus isolation, and c) mindfulness versus
over-identification. Daily attention. The Mindful Attention
Awareness Scale (MAAS [49]) is administered before each
MBCT session to assess mindful attention in daily life.
Positive and negative affect is assessed before each MBCT
session using the International Positive and Negative Affect
Scale - Short Form (I-PANAS-SF [50]).
Cost-effectiveness
The cost-effectiveness evaluation is carried out from a
societal perspective considering direct as well as indirect
health costs. Data on health and social care utilization
are collected prospectively for each individual patient
using an adapted version of the Client Service Receipt
Inventory (CSRI [51]). The CSRI includes production
losses and family support. In addition prospective data
are collected using a daily calendar on which partici-
pants register a) depression-related absence from work:
full absence, partial absence or no absence, and b) any
contacts with health care: the type of care and its dur-
ation. Unit cost estimates are derived from the national
manual for cost prices in the health care sector [52].
Costs of reduced ability to work are estimated using the
friction costs method, which results in a more realistic
estimate than the human capital approach [53]. Treat-
ment costs of MBCT are calculated using activity-based-
costing methods, thus measuring actual resources (time
of therapist, time of patients, facilities) used. All unit
cost prices are adjusted to 2012 prices. Unit cost esti-
mates are combined with resource utilization data to
obtain a net cost per patient over the entire follow-up
period. The EuroQoL-5 Dimensions instrument (EQ-5D
[54]) is administered to provide utilities. The EQ-5D
consists of 5 dimensions: mobility, self-care, daily activ-
ities, pain/discomfort and anxiety/depression. In
addition, it contains a Visual Analogue Scale to deter-
mine Quality Adjusted Life Years (QALYs).
Procedure
Assessment of eligibility informed consent and baseline
assessment
Figure 1 provides an overview of the recruitment and
study procedure. After informed consent is obtained eli-
gibility is assessed during the baseline interview (T0)
using the SCID I depression module, the IDS-C, and the
MINI (modules bipolar disorder, psychotic disorder, al-
cohol and drug dependency). After randomization, the
participant is informed about the condition to which he
or she has been randomized. Also, the baseline question-
naires are administered at T0 (see Table 1).
Randomization
Randomization is computerized using a minimization
strategy while stratifying over the following variables: a)
research centre, b) full versus partial remission (IDS-C
score ≤ 11 versus > 11), c) number of depressive episodes
in the past (3-4 versus ≥ 5), d) prior CBT (yes/no) and e)
gender. Sub–threshold symptoms (partial remission) and
number of past episodes are stratified because both are
associated with relapse/recurrence risk [55]. Also, prior
CBT is stratified because this has been shown to de-
crease relapse/recurrence risk [56]. Randomization is
performed online by the research assistant who conducts
the baseline assessment by entering the required infor-
mation on a randomization website specifically designed
for this study. The research assistant then communicates
the treatment allocation to the patient, which means that
he or she is no longer blind to the treatment condition.
Unblinding of patients and research-assistants could not
be avoided because the different conditions required dif-
ferent arrangements for treatment appointments, and
separating this task from the assessments was logistically
impossible in most research centers. To assess the reli-
ability of the follow-up assessments, all interviews are
audio taped and a random selection of actual, borderline
or probable cases of relapse/recurrence is rated by an in-
dependent assistant blind to treatment allocation.
Follow-up assessments
In accordance with previous trials [19,20,23], follow-up
assessments take place at 3, 6, 9, 12 and 15 months post
randomization (Table 1). The follow-up assessments at
T2, T3 and T4 are administered by telephone and con-
sist of only an interview part. If participants miss one or
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more assessments, research assistants examine the entire
period from the last contact. In case of drop-out, we
send a short questionnaire to gather essential informa-
tion about depressive relapse/recurrence (if applicable)
and the main reason for drop-out.
Statistical analysis
Primary analyses
Our primary analyses will be based on intention-to-treat.
Subsequently per-protocol analyses will be conducted.
All analyses will be performed with and without covari-
ates (i.e. the stratification factors research centre, depres-
sive symptoms at baseline, and number of depressive
episodes in the past, as well as other variables that might
inadvertently be unevenly distributed over the condi-
tions at baseline). Trial 1: mADM versus mADM+
MBCT. The primary outcome measure will be relapse
and/or recurrence meeting DSM-IV criteria for a major
depressive episode during the 15-month study period.
Relapse/recurrence rates will be compared with a Chi-
square test. Trial 2: MBCT versus mADM+MBCT. The
primary outcome measure will be relapse and/or recur-
rence meeting DSM-IV criteria for a major depressive
episode during the 15-month study period. Relapse/
recurrence rates will be compared with a General Linear
Model using a binomial family with an identity link. We
will use the confidence interval (one-sided) of the differ-
ence in relapse/recurrence between the two conditions
(MBCT versus mADM+MBCT): if a difference of 25%
can be excluded, then we will conclude non-inferiority of
MBCT in comparison with mADM.
Secondary analyses
Time to relapse and number, duration and severity
of relapse/recurrence Differences in time to relapse/
recurrence between mADM versus mADM+MBCT
(trial 1) and between MBCT versus mADM+MBCT
(trial 2) will be analyzed using a Cox Regression Propor-
tional Hazards Model. In case of drop-out from the trial
we will use the available measures and censor the partici-
pant at the time of the last assessment or informative
contact. In patients suffering a relapse/recurrence during
the study period we will compare the number, duration
and severity of relapse/recurrence between mADM ver-
sus mADM + MBCT (trial 1) and between MBCT versus
mADM+MBCT (trial 2) using a General Linear Model.
We will perform additional analyses comparing different
subgroups, for example patients who were in full remis-
sion at baseline (IDS-C ≤ 11) with patients who were in
partial remission at baseline (IDS-C > 11) for both trials.
Mechanisms of change Mediation analyses will be used
to investigate the possible underlying mechanisms of
change in MBCT. In accordance with other trials, these
analyses will only include patients who have received an
‘adequate dose’ of MBCT, which is defined as participation
in ≥ 4 of 8 MBCT sessions [16,19]. In this subsample, we
will test the mediating effect of adherence to MBCT,
rumination, cognitive reactivity, mindfulness skills, and
self-compassion, on depressive relapse/recurrence and de-
pression severity as outcomes, using a multiple mediation
model following the approach suggested by Preacher and
Hayes [57]. In addition, we will use Hierarchical Linear
Modeling techniques to investigate whether change in daily
attention/awareness causally influences positive and nega-
tive effect. We will perform multilevel mediational analyses
following the procedure reported by Kenny, Korchmaros &
Bolger [58]. We will ‘lag’ the mediator variable (daily atten-
tion/awareness) by examining whether changes on the
MAAS at time t-1 account for changes in the outcome
variable (i.e. positive and negative affect) at time t for every
MBCT session.
Cost-effectiveness Cost-effectiveness of mADM versus
mADM+MBCT will be analyzed in trial 1 and cost-
effectiveness of MBCT versus mADM+MBCT will be
analyzed in trial 2. A non-parametric bootstrapping
method will be used, performing 1000 replications of the
original data to produce confidence intervals. Changes in
health-related quality of life from baseline will be used to
calculate QALYs in each group. Incremental cost-
effectiveness will be expressed in terms of incremental
costs per QALY gained. A cost-acceptability curve will
be constructed for statistical analysis of the incremental
cost-effectiveness ratio. In case of dominance a full cost
analysis will be conducted to estimate the mean savings
per patient per year. To estimate the long-term conse-
quences of introducing MBCT in the prevention of
relapse/recurrence, decision analytic modeling (Tree-
Age) will be used, comparing mADM, MBCT, and the
combination of mADM and MBCT in patients with
recurrent depression, over a period of 5 years. Estimates
of costs, utilities, and probabilities will be derived from
the trial (extrapolation) and, where available, the litera-
ture, or from experts. Sensitivity analyses will be con-
ducted to explore sensitivity of the outcomes to various
model assumptions.
Discussion
The prevention of relapse and recurrence in depression
is considered a key target in mental health care given
the high prevalence of relapse/recurrence of MDD and
the accompanying (societal) costs. Previous studies have
shown that MBCT significantly reduces the relapse/
recurrence risk as compared to treatment as usual [25],
but MBCT has not yet been studied as an additional
treatment to mADM. Therefore, our first trial will inform
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health care professionals and patients about the relapse/
recurrence risks associated with MBCT in addition to
mADM compared with continuing mADM on its own.
However, given the large amount of patients who prefer
psychological treatment instead of ADM [9] and the diffi-
culties that many patients have with long term use of
ADM [7], it seems useful to investigate whether a rela-
tively short, group-based course such as MBCT can help
patients taper off their antidepressants. Therefore, our
second trial will inform patients and clinicians about the
relapse/recurrence risks associated with tapering off
mADM after MBCT, compared with continuing mADM
after MBCT. This trial is based on non-inferiority be-
cause we reasoned that the effectiveness of MBCT on its
own (i.e. discontinuing antidepressants after MBCT)
should be at least comparable to the effectiveness of
mADM on its own. The original study design was an
RCT comparing mADM, MBCT, and mADM+MBCT.
However, because of the strong treatment preferences
that patients expressed during the beginning of the re-
cruitment phase which hampered the randomization
possibilities, we adapted our design. Instead of a direct
comparison between the three treatment options (three-
way randomization) we now allocate the patients to dif-
ferent RCTs based on their preference for either mADM
(allocation between mADM and mADM+MBCT) or for
MBCT (allocation between MBCT and mADM+
MBCT). A methodological consequence of this adapta-
tion is that we cannot directly compare MBCT to
mADM because the MBCT preference group may differ
from the mADM preference group with respect to
known as well as unknown variables. The advantage that
comes along with this design however, is an increase in
the ecological validity of both trials. In our adapted de-
sign, the included patient groups probably more closely
reflect the population(s) that we are interested in, since
these preferences are obviously present in the population
of remitted recurrently depressed adults who use
mADM. Moreover, if we had continued using the original
three-way randomization procedure, we would have lost
all participants who were not willing to be randomly
assigned to mADM only or to MBCT only, resulting in a
highly selective sample with low generalizability. In sum-
mary, more detailed knowledge about the effectiveness of
MBCT in addition to mADM, and about MBCT as a pos-
sible alternative to mADM is needed. Taking into ac-
count patient preferences, the MOMENT study will
address these questions to support patients and clinicians
in finding the optimal strategy to prevent depressive
relapse and recurrence.
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